Risk factors of pancreatic leakage after pancreaticoduodenectomy

Yin-Mo Yang, Xiao-Dong Tian, Yan Zhuang, Wei-Min Wang, Yuan-Lian Wan, Yan-Ting Huang

INTRODUCTION

Pancreaticoduodenectomy (PD) is one of the standard treatments for various benign and malignant diseases of the pancreatic head and periampullary region. Recently, the
operative mortality rate after PD has significantly declined, while the incidence of postoperative morbidity remains high, from 40% to 50%\textsuperscript{[4-8]}. Pancreatic fistula is the major source of complications, and leakage rate varies from 0% to 25%, according to recent reports\textsuperscript{[6-8]}. Abdominal abscess and hemorrhage are common sequelae of pancreatic anastomotic leakage, which have been associated with a mortality rate of 40% or more. Subsequently, pancreatic fistula has become one of the major complications discouraging surgeons from performing PD\textsuperscript{[6-8,10]}. Recent literature suggests that many factors influence pancreatic leakage after PD, including sex, age, jaundice, operation time, intraoperative blood loss, pancreaticojejunal anastomotic technique, texture of the remnant pancreas, pancreatic duct size, use of somatostatin, and surgeon experience. However, no definite factor has yet been identified. Some authors have compared the incidence of pancreatic leakage with various techniques of anastomosis, such as invagination pancreaticojejunal anastomosis, duct-to-mucosa pancreaticojejunal anastomosis, pancreaticogastrostomy, pancreatic duct ligation, and their modifications. No conclusions though can be drawn to demonstrate which technique is best and suitable for any particular case. To analyze perioperative risk factors for pancreatic leakage after PD and to compare duct-to-mucosa with invagination pancreaticojejunal anastomosis, we reviewed retrospectively 62 cases that underwent PD at our hospital.

MATERIALS AND METHODS
Between January 2000 and November 2003, 62 patients underwent PD at our hospital, including 38 men and 24 women. Patients' age ranged from 33 to 77 years, with a mean age of 57.53 years. Before surgery, jaundice was found in 30 cases and 3 cases had hypoproteinemia. The diagnoses are shown in Table 1. All of the diseases were confirmed by pathologic examinations.

| Diseases                        | No. of patients (n = 62) | Surgical techniques |
|---------------------------------|--------------------------|---------------------|
|                                 | PD (n = 52) | PPPD (n = 10) |
| Pancreas cancer                 | 29          | 26        | 3        |
| Ampullary cancer                | 14          | 10        | 4        |
| Bile duct cancer                | 13          | 12        | 1        |
| Islet cell cancer               | 2           | 1         | 1        |
| Duodenal cancer                 | 1           | 1         | 0        |
| Chronic pancreatitis            | 1           | 1         | 0        |
| Pancreatic cystadenoma          | 1           | 1         | 1        |
| Gastric cancer                  | 1           | 1         | 0        |

PD: pancreaticoduodenectomy; PPPD: pylorus-preserving pancreaticoduodenectomy.

Surgical techniques
In the 62 cases, standard PD was performed for 25 patients, PD with extended lymphadenectomy for 27 patients, and PPPD for 10 patients. One patient with gastric cancer invading the peripancreas region underwent radical gastroscopy and PD with extended lymphadenectomy. In all cases, two drainage tubes were placed posterior to the biliary and pancreatic anastomoses. The selection of various pancreaticojejunal anastomotic techniques was based on pancreatic duct size and texture of the remnant pancreas. A duct-to-mucosa pancreaticojejunal anastomosis was performed for patients with a hard pancreas and a dilated pancreatic duct (diameter ≥ 3 mm) (Figure 1). Posterior suture was achieved with 3-0 silk sutures between the posterior capsular parenchyma of the pancreatic remnant and the seromuscular layer of the jejunum. At the site for anastomosis to the main pancreatic duct, a small opening was made on the antimesenteric side of the jejunal wall according to the site and diameter of the pancreatic duct.

Then anastomosis between the pancreatic duct and jejunum (all layers) was performed with 6-0 Prolene interrupted sutures at intervals of approximately 1 mm, from the posterior layer to the anterior layer, with all knots out of the anastomosis. Next, suture of the anterior side of the anastomosis between the pancreatic capsular parenchyma and the jejunal seromuscular layer was made by the same technique as used for the posterior side. No pancreatic duct drainage was used in cases undergoing duct-to-mucosa anastomotic technique (Figure 2). A traditional end-to-end or end-to-side invagination pancreaticojejunal anastomosis was performed for patients with a soft pancreas and a non-dilated duct. The pancreas remnant was invaginated into the jejunum by about 2 cm, and two-layer sutures were performed interruptedly, with an internal duct stent tube inserted in the pancreatic duct.

Figure 1 End-to-side duct-to-mucosa pancreaticojejunal anastomosis.

Prophylactic use of somatostatin after PD was based on the experience of the surgeon and satisfactory degree of the anastomosis. Octreotide was used for 5-7 d postoperatively, 0.3 mg per d by subcutaneous injection.

Study design and statistical analysis
Pancreaticojejunal anastomotic leakage was defined as: (1) discharge from the postpancreatic drain ≥50 mL/d after postoperative d 3, and (2) an amylase level of drainage fluid exceeding three times of the serum concentration.

Patients were divided into two groups according to the above criteria: 10 cases with postoperative pancreaticojejunal anastomotic leakage (leakage group) and 52 cases without leakage (nonleakage group). Seven general factors and six intraoperative clinical factors with the potential to affect the incidence of pancreaticojejunal anastomotic leakage were analyzed. Statistical computations were done with the SPSS10.0 software. Data were expressed as mean±SE, and percentage was used to express grouped data. The two groups were
first compared by the univariate statistical tests, t-test, rank sum test, χ² test or Fisher’s exact test, when applicable (Tables 2 and 3). Logistic regression was then used to determine the effect of multiple factors on pancreatic leakage (Table 4). P less than 0.05 was considered statistically significant.

**RESULTS**

**Complications**

Of the 62 patients, 10 (16.1%) were identified as having pancreatic leakage after operation. Other major postoperative complications included delayed gastric emptying (eight patients), abdominal bleeding (four patients), abdominal abscess (three patients) and wound infection (two patients). Overall surgical morbidity was 43.5% (27/62). One patient died of massive abdominal hemorrhage associated with pancreatic fistula 10 d after operation, and two died of abdominal bleeding within 3 d after operation. The hospital mortality in this series was 4.84% (3/62), and the mortality associated with pancreatic fistula was 10% (1/10). One patient required reoperation because of abdominal bleeding, but no pancreaticojejunal anastomotic leakage was found in this patient.

**Risk factors**

General risk factors were compared for patients with or without pancreatic leakage (Table 2). Patient age, gender, history of jaundice, preoperative nutrition, pathological diagnosis and the length of postoperative stay were similar in the two groups. The incidence of pancreatic fistula was 20.7% (6/29) in the two patient groups. Moreover, multivariate logistic regression analysis showed that none of these factors seemed to be associated with pancreatic fistula.

Two intraoperative risk factors were found to be significantly associated with pancreatic leakage: pancreatic duct size and texture of the remnant pancreas. The incidence of pancreatic leakage was 4.88% in patients with a pancreatic duct size greater than or equal to 3 mm, and was 38.1% in those with ducts smaller than 3 mm (P = 0.002). The pancreatic leakage rate was 2.94% in patients with a hard pancreas, and was 32.1% in those with a soft pancreas (P = 0.004). Operative time, blood loss and type of resection were similar in the two patient groups. The incidence of pancreatic leakage was 6.25% (1/16) in patients with duct-to-mucosa anastomosis, and was 19.6% (9/46) in those with traditional invagination anastomosis. Although the difference of pancreatic leakage between the two groups was obvious, no statistical significance was found. This may be due to the small number of patients with duct-to-mucosa anastomosis.

The three factors affecting pancreatic leakage were further analyzed by multivariate logistic regression. Both pancreatic duct size and texture of the remnant pancreas were demonstrated to be independent risk factors (Table 3). Patients with a small pancreatic duct or a soft pancreas were at high risk of pancreatic leakage.

### Table 2 General risk factors for pancreatic leakage [n (%)]

| Parameters | Leakage group (n = 12) | Nonleakage group (n = 45) | P |
|------------|------------------------|---------------------------|---|
| Age (yr)   | 59.8±10.04             | 57.1±11.37                | 0.487 |
| Gender     |                        |                           | 0.166 |
| Male       | 4 (10.5)¹               | 34 (79.5)¹                |     |
| Female     | 6 (25)¹                 | 18 (75)¹                  |     |
| History of jaundice |               |                           | 0.733 |
| Yes        | 4 (13.3)¹               | 26 (66.7)¹                |     |
| No         | 6 (18.8)¹               | 28 (61.2)¹                |     |
| Preoperative serum-albumin |           |                           | >0.95 |
| Normal     | 10 (66.7)¹              | 49 (83.1)¹                |     |
| Low        | 0 (0)²                  | 3 (100)³                  |     |
| Pathology  |                        |                           | 0.312² |
| Pancreas cancer |                |                           |     |
| Ampullary cancer |               |                           |     |
| Bile duct cancer |               |                           |     |
| Islet cell tumor |               |                           |     |
| Duodenal cancer |               |                           |     |
| Chronic pancreatitis |           |                           |     |
| Pancreatic cystadenoma |           |                           |     |
| Gastric cancer |                 |                           |     |
| Octreotide |                        |                           | 0.493 |
| Used       | 6 (20.7)¹               | 23 (79.3)¹                |     |
| Non-used   | 4 (12.1)¹               | 29 (87.9)¹                |     |
| Postoperative stay (d) |             |                           | 0.177 |

### Table 3 Intraoperative risk factors for pancreatic leakage [n (%)]

| Parameters | Leakage group (n = 12) | Nonleakage group (n = 45) | P |
|------------|------------------------|---------------------------|---|
| Age (yr)   | 59.8±10.04             | 57.1±11.37                | 0.487 |
| Gender     |                        |                           | 0.166 |
| Male       | 4 (10.5)¹               | 34 (79.5)¹                |     |
| Female     | 6 (25)¹                 | 18 (75)¹                  |     |
| History of jaundice |               |                           | 0.733 |
| Yes        | 4 (13.3)¹               | 26 (66.7)¹                |     |
| No         | 6 (18.8)¹               | 28 (61.2)¹                |     |
| Preoperative serum-albumin |           |                           | >0.95 |
| Normal     | 10 (66.7)¹              | 49 (83.1)¹                |     |
| Low        | 0 (0)²                  | 3 (100)³                  |     |
| Pathology  |                        |                           | 0.312² |
| Pancreas cancer |                |                           |     |
| Ampullary cancer |               |                           |     |
| Bile duct cancer |               |                           |     |
| Islet cell tumor |               |                           |     |
| Duodenal cancer |               |                           |     |
| Chronic pancreatitis |           |                           |     |
| Pancreatic cystadenoma |           |                           |     |
| Gastric cancer |                 |                           |     |
| Octreotide |                        |                           | 0.493 |
| Used       | 6 (20.7)¹               | 23 (79.3)¹                |     |
| Non-used   | 4 (12.1)¹               | 29 (87.9)¹                |     |
| Postoperative stay (d) |             |                           | 0.177 |

### Table 4 Multivariate logistic regression for pancreatic leakage

| Parameters | P | Odds ratio | CI |
|------------|---|------------|----|
| Age (yr)   | 0.487 |           |    |
| Gender     | 0.166 |           |    |
| Male       | 0.188 |           |    |
| Female     | 0.166 |           |    |
| History of jaundice |               |   |
| Yes        | 0.733 |           |    |
| No         | 0.733 |           |    |
| Pathology  | 0.312² |          |    |
| Pancreas cancer |               |   |
| Ampullary cancer |               |   |
| Bile duct cancer |               |   |
| Islet cell tumor |               |   |
| Duodenal cancer |               |   |
| Chronic pancreatitis |           |    |
| Pancreatic cystadenoma |           |    |
| Gastric cancer |                 |   |
| Octreotide | 0.493 |           |    |
| Used       | 0.493 |           |    |
| Non-used   | 0.493 |           |    |
| Postoperative stay (d) | 0.493 |          |    |

CI: 95% confidence intervals.
Treatment and outcome
All the 10 patients who developed pancreatic leakage were diagnosed on the basis of the total amount and concentration of amylase in postpancreatic drainage exudate. One patient had abdominal massive hemorrhage, and two had abdominal abscess, the rest were successfully managed by conservative treatment. In five patients, a prolonged drainage duration for 4 wk after surgery was required. Octreotide was administered to five patients, including two with ineffective drains requiring another percutaneous drainage.

DISCUSSION
In recent years, PD has been used increasingly as a safe method of resection in patients with malignant and benign disorders of the pancreas and peripancreatic region. Although postoperative mortality has decreased significantly, the incidence of postoperative morbidity is still high. The overall surgical morbidity after PD was 43.5% (27/62), and the incidence of pancreatic leakage was 16.1% (10/62), similar to recent literature reports.

Risk factors for pancreatic anastomotic leakage after PD
Risk factors for pancreatic leakage include general factors (age, gender, jaundice, malnutrition), disease factors (pancreatic pathology, pancreatic texture, pancreatic duct size, pancreatic juice output) and procedure-related factors (operative time, resection type, anastomotic technique, intraoperative blood loss). In addition, surgeon experience has been shown to correlate with pancreatic anastomotic leakage rate, and prophylactic use of somatostatin has also been reported in recent literature to influence pancreatic leakage.

It has been widely accepted that a fibrotic pancreatic remnant in patients with chronic pancreatitis facilitates the pancreaticoenteric anastomosis, whereas a soft and friable pancreatic parenchyma makes the anastomosis difficult to perform. Yeo et al. found that there was a strong association between the pancreatic texture and pancreatic leakage. None of the 53 patients with hard pancreatic remnants developed pancreatic leakage, whereas 25% (19/75) of patients with soft pancreatic texture were complicated by pancreatic leakage. Hosotani et al. reviewed 161 patients who had undergone PD and reported a fistula rate of 11% (17/161), finding that pancreaticojejunostomy anastomotic technique, pancreatic texture and pancreatic duct size were substantial risk factors for pancreatic leakage after PD. In a study by Marcus et al., male sex was found to be a significant factor predisposing pancreatic fistula. A recent study by Yeh et al., identified jaundice, creatinine clearance abnormality, and intraoperative blood loss as significant risk factors for leakage. Matsusue et al., found that advanced age (>70 years) was an adverse factor for pancreatic leakage.

Inhibition of exocrine pancreatic secretion may reduce the anastomotic fistula rate after PD. In recent years, more importance has been attached to prophylactic use of somatostatin after PD, but no consensus has been achieved. European studies found that prophylactic octreotide in pancreatic resection could reduce total morbidity rate or pancreatic fistula rate, though none of them demonstrated a decrease in the overall mortality rate. In another report, a significantly lower pancreatic fistula rate was observed with the use of octreotide among patients who underwent distal pancreatectomy or local pancreatic resection, whereas no statistical difference was noted between octreotide and...
placebo groups in patients who underwent PD[15]. Yeo et al[16], recently randomized 211 patients who underwent PD into saline control and octreotide groups. The pancreatic fistula rate in the octreotide group was 11%, and 9% in the control group. The authors concluded that prophylactic use of octreotide after PD could not reduce the pancreatic fistula rate[10]. Poon et al[17], studied the meta-analysis of six prospective randomized trials on the prophylactic use of octreotide in pancreatic resection and published them as full reports in the literature from January 1990 to December 2000. The meta-analysis did not show any beneficial effect of octreotide on pancreatic anastomotic leakage rate.

In this study, we analyzed 13 general or intraoperative factors. Two intraoperative factors were significantly associated with the risk of pancreatic leakage: pancreatic duct size and texture of the remnant pancreas. Multivariate analysis also revealed that the two factors turned out to be independent risk factors. Prophylactic use of octreotide after PD did not result in a decline of the pancreatic fistula rate.

**Anastomotic techniques and pancreatic leakage**

Management of the pancreatic remnant after PD is regarded as the key point to reduce pancreatic leakage. Various reconstruction techniques have been developed to diminish pancreatic fistulae, such as duct-to-mucosa pancreatico-jejunostomy, invagination pancreaticojejunostomy, pancreaticogastrostomy, use of a transanastomotic stenting tube, and their modifications. Ligation or obliteration of the pancreatic duct has not been popularized as they abolish the pancreatic exocrine secretion, with still a high incidence of pancreatic leakage[20,21].

Reviewing various techniques of pancreaticojejunostomy in the literatures published over the last decade, Poon et al[17], found that duct-to-mucosa anastomosis was a safer technique than invagination anastomosis. Marcus et al[22], found that duct-to-mucosa anastomosis was associated with a low pancreatic fistula rate in low-risk patients with a dilated pancreatic duct or a fibrotic pancreas, whereas end-to-end invagination technique was safer in high-risk patients with small ducts or a soft friable pancreas. Suzuki et al[23], selected various pancreaticojejunostomy techniques according to the pancreatic texture and duct size, and obtained an overall pancreatic leakage rate of 8% (4/50). All of the patients who developed pancreatic fistulae were all with a small duct and a soft pancreas. In that series, the incidence of pancreatic leakage rate was 6.25% in patients who underwent a duct-to-mucosa pancreaticojejunostomy anastomosis, compared to 19.6% in invagation group. The difference, of course, resulted from the variation of anastomotic techniques; while all of the patients who received the duct-to-mucosa anastomosis, on the other hand, were with a dilated pancreatic duct (≥3 mm) or a soft pancreas. Therefore, both of the two factors might be associated with the discrepancy of the pancreatic leakage rate in the two groups.

There has been no conclusion as to whether a pancreatic duct stent for internal or external drainage can reduce the pancreatic leakage rate after PD. According to the authors who recommended it, a stent might help drain the pancreatic secretion juice from the anastomosis, and allow a more precise placement of sutures, thus protecting the pancreatic duct from injury and reducing fistula rate[24-27]. Some investigators found a few drawbacks to this method, such as accidental removal of the stent, obstruction or bending of the stenting tube, which might increase the incidence of pancreatic leakage. However, the overall pancreatic leakage rate in patients with a pancreatic stent was found to be similar to that in patients without a stent[28]. Therefore, as far as invagination anastomosis is concerned, it is safer to use an internal drainage stent for patients with a small pancreatic duct and a soft pancreas.

**Appraisal of duct-to-mucosa pancreaticojejunostomy**

Duct-to-mucosa pancreaticojejunostomy anastomosis was first used by Cattel in 1943. This technique allows direct contact of the pancreatic duct with jejunal mucosa, preventing direct contact of pancreatic juice with the cut end of the pancreas and thus helping healing of the mucosa, protecting the anastomosis by embedding the pancreatic remnant under jejunal serosa. Therefore, duct-to-mucosa anastomosis is a theoretically more rational technique to avoid pancreatic fistulae. Since it is technically difficult to perform, duct-to-mucosa pancreaticojejunostomy anastomosis was previously recommended for patients with a dilated pancreatic duct, whereas in recent years this technique has been preferred regardless of the diameter of the pancreatic duct[11,29]. Hosotani et al[30], using multivariate analysis found that only pancreaticojejunostomy technique turned out to be an independent risk factor and duct-to-mucosa anastomosis pancreaticojejunostomy reduced the risk of pancreatic leakage after PD (odds ratio = 4.15). In our hospital, invagination pancreaticojejunostomy anastomosis was performed for patients with either a dilated or a non-dilated pancreatic duct before 2000, with a consistent high pancreatic leakage rate. From 2000, duct-to-mucosa pancreaticojejunostomy anastomosis has been performed for patients with a dilated pancreatic duct, and the pancreaticojejunostomy anastomotic leakage rate has declined significantly when compared with previous invagination anastomosis, though no statistical difference was found in the present study.

Based on accumulated evidence so far, no conclusion could be drawn to appraise various anastomotic techniques, since most pertinent articles were retrospective studies. In prospective studies, most were not randomized controlled trials. On the other hand, anastomotic leakage rate is greatly related to the surgery technique and experience, which cannot be easily compared among different institutions. The need for a prospective randomized controlled trial by the same surgeons to evaluate various anastomotic techniques is highlighted. In conclusion, anastomotic techniques should be selected based on the status of the remnant pancreas intraoperatively: duct-to-mucosa anastomosis without a pancreatic duct stent for patients with a dilated pancreatic duct (≥3 mm), and invagination anastomosis with an internal drainage stent for patients with a small pancreatic duct and a soft pancreas.

**REFERENCES**

1. Neoptolemos JP, Russell RC, Bramhall S, Theis B. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic
units. UK Pancreatic Cancer Group. Br J Surg 1997; 84: 1370-1376

2 Botteger TC, Junginger T. Factors influencing morbidity and mortality after pancreaticoduodenectomy: critical analysis of 221 resections. World J Surg 1999; 23: 164-171; discussion 171-172

3 Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kaufman HS, Coleman J. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 1993; 217: 430-435; discussion 435-438

4 Fernandez-del Castillo C, Rattner DW, Warshaw AL. Standards for pancreatic resection in the 1990s. Arch Surg 1995; 130: 295-299; discussion 299-300

5 Jimenez RE, Fernandez-del Castillo C, Rattner DW, Chang Y, Warshaw AL. Outcome of pancreaticoduodenectomy with pylorus preservation or with antrectomy in the treatment of chronic pancreatitis. Ann Surg 2000; 231: 293-300

6 Trede M, Schwall G. The complications of pancreatectomy. Ann Surg 1988; 207: 39-47

7 Cullen JJ, Sarr MG, Istrup DM. Pancreatic anastomotic leak after pancreaticoduodenectomy: incidence, significance, and management. Am J Surg 1994; 168: 295-298

8 Strasberg SM, Drebin JA, Soper NJ. Evolution and current status of the Whipple procedure: an update for gastroenterologists. Gastroenterology 1997; 113: 983-994

9 van Berge Henegouwen MI, De Wit LT, Van Gulik TM, Obertop H, Gouma DJ. Incidence, risk factors, and treatment of pancreatic leakage after pancreaticoduodenectomy: drainage versus resection of the pancreatic remnant. J Am Coll Surg 1997; 185: 18-24

10 Yeo CJ, Cameron JL, Lillemoe KD, Sauer PK, Coleman J, Sohn TA, Campbell KA, Choti MA. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 2000; 232: 419-429

11 Hosotani R, Doi R, Imamura M. Duct-to-mucosa pancreaticojejunostomy reduces the risk of pancreatic leakage after pancreateoduodenectomy. World J Surg 2002; 26: 99-104

12 Marcus SG, Cohen H, Ranson JH. Optimal management of the pancreatic remnant after pancreaticoduodenectomy. Ann Surg 1995; 221: 635-645; discussion 645-648

13 Yeh TS, Jan YY, Jeng LB, Hwang TL, Wang CS, Chen SC, Chao TC, Chen MF. Pancreaticojunal anastomotic leak after pancreaticoduodenectomy--multivariate analysis of perioperative risk factors. J Surg Res 1997; 67: 119-125

14 Matsusue S, Takeda H, Nakamura Y, Nishimura S, Koizumi S. A prospective analysis of the factors influencing pancreaticojunalostomy performed using a single method, in 100 consecutive pancreaticoduodenectomies. Surg Today 1998; 28: 719-726

15 Montorsi M, Zago M, Mosca F, Capussotti L, Zotti E, Ribotta G, Fegiz G, Fissi S, Roviaro G, Peracchia A. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial. Surgery 1995; 117: 26-31

16 Buchler M, Friess H, Klempa J, Hermanek P, Sulkowski U, Becker H, Schafmayer A, Baci I, Lorenz D, Meister R. Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg 1992; 163: 125-130; discussion 130-131

17 Friess H, Beger HG, Sulkowski U, Becker H, Hofbauer B, Dernier HJ, Buchler MW. Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. Br J Surg 1995; 82: 1270-1273

18 Pedezzoli P, Bassi C, Falconi M, Camboni MG. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Italian Study Group. Br J Surg 1994; 81: 265-269

19 Poon RT, Lo SH, Fong D, Fan ST, Wong J. Prevention of pancreatic anastomotic leakage after pancreaticoduodenectomy. Am J Surg 2002; 183: 42-52

20 Bartoli FG, Arnone GB, Rainer G, Bachi V. Pancreatic fistula and relative mortality in malignant disease after pancreaticoduodenectomy. Review and statistical meta-analysis regarding 15 years of literature. Anticancer Res 1991; 11: 1831-1848

21 Marcelli AP, Stierer M. Partial pancreaticoduodenectomy (Whipple procedure) for pancreatic malignancy: occlusion of a non-anastomosed pancreatic stump with fibrin sealant. HPB Surg 1992; 5: 251-259; discussion 259-260

22 Di Carlo V, Chiesa R, Pontiroli AE, Carlucchi M, Staudacher C, Zerbi A, Cristallo M, Braga M, Pozza G. Pancreatoduodenectomy with occlusion of the residual stump by Neoprene injection. World J Surg 1989; 13: 105-110; discussion 110-111

23 Suzuki Y, Fujino Y, Tanioka Y, Hiraoka K, Takada M, Ajiki T, Takeyama Y, Ku Y, Kuroda Y. Selection of pancreaticojunalostomy techniques according to pancreatic texture and duct size. Arch Surg 2002; 137: 1044-1047; discussion 1048

24 Hamanaka Y, Suzuki T. Total pancreatic duct drainage for leakproof pancreateojunalostomy. Surgery 1994; 115: 22-26

25 Mok KT, Wang BW, Liu SI. Management of pancreatic remnant with strategies according to the size of pancreatic duct after pancreateoduodenectomy. Br J Surg 1999; 86: 1018-1019

26 Yoshihi F, Ono H, Asato Y, Ohta T, Koizumi S, Amemiya R, Hasegawa H. Internal stenting of the hepaticojunalostomy and pancreateojunalostomy in patients undergoing pancreateoduodenectomy to promote earlier discharge from hospital. Surg Today 1996; 26: 665-667

27 Roder JD, Stein HJ, Bottcher KA, Busch R, Heidecke CD, Sievert JR. Stented versus nonstented pancreateojunalostomy after pancreateoduodenectomy: a prospective study. Ann Surg 1999; 229: 41-48

28 Imaiizumi T, Harada N, Hatori T, Fukuda A, Takasaki K. Stenting is unnecessary in duct-to-mucosa pancreateojunalostomy even in the normal pancreas. Pancreatology 2002; 2: 116-121

29 Howard JM. Pancreateojunalostomy: leakage is a preventable complication of the Whipple resection. J Am Coll Surg 1997; 184: 454-457